

Red Blood Cell Molecular Testing

Policy Number: AHS – M2170 – Red Blood Cell Molecular Testing	Policy Revision Date: 10/15/2025 Initial Policy Effective Date: 12/01/2024
---	---

[POLICY DESCRIPTION](#) | [RELATED POLICIES](#) | [INDICATIONS AND/OR LIMITATIONS OF COVERAGE](#) | [TABLE OF TERMINOLOGY](#) | [SCIENTIFIC BACKGROUND](#) | [GUIDELINES AND RECOMMENDATIONS](#) | [APPLICABLE STATE AND FEDERAL REGULATIONS](#) | [APPLICABLE CPT/HCPCS PROCEDURE CODES](#) | [EVIDENCE-BASED SCIENTIFIC REFERENCES](#) | [REVISION HISTORY](#)

I. Policy Description

The first successful blood transfusion can be dated back to the 1600s.¹ Molecular testing methods to analyze blood samples were introduced to the transfusion medicine community in the 1990s.² Several ailments warrant a blood transfusion and the phenotypic and genotypic determination of red blood cell antigens assist in limiting immune responses in transfusion patients. Agglutination tests via serology have been the gold standard for determining blood group antigens for more than 100 years,³ yet newer molecular techniques may grant added specificity.⁴

For guidance regarding fetal RHD genotyping in RHD negative pregnant individuals, please refer to AHS-M2179-Prenatal Screening (Genetic).

II. Related Policies

Policy Number	Policy Title
AHS-M2131	Genetic Testing for Alpha- and Beta-Thalassemia
AHS-M2179	Prenatal Screening (Genetic)

III. Indications and/or Limitations of Coverage

Application of coverage criteria is dependent upon an individual’s benefit coverage at the time of the request. Specifications pertaining to Medicare and Medicaid can be found in the “Applicable State and Federal Regulations” section of this policy document.

- 1) Red cell genotyping (including C, c, D, E, e, K, k, Jka, Jkb, Fya, Fyb, S, s, U) **MEETS COVERAGE CRITERIA** in **any** of the following situations:
 - a) For individuals with sickle cell disease, thalassemia syndromes, hemoglobinopathies, and/or other medical conditions requiring recurring transfusions.
 - b) For individuals with post-transfusion hemolysis, when no antibodies are detectable and no other possible cause is known (e.g., sickle cell crisis, mechanical hemolysis due to heart valve failure).
 - c) For individuals with autoimmune hemolytic anemia.
 - d) For multiply transfused individuals and/or individuals who are direct antiglobulin test positive.
 - e) For pregnant individuals who, prior to their first transfusion, had non-transfusion-dependent thalassemia.

- f) To help manage hemolytic disease of the fetus and newborn.
 - g) To resolve conflicting serological antibody results.
 - h) For individuals with suspected Duffy-null neutropenia.
- 2) Red cell genotyping (including C, c, D, E, e, K, k, Jka, Jkb, Fya, Fyb, S, s, U) **DOES NOT MEET COVERAGE CRITERIA** in **any** of the following situations:
- a) For individuals who have had allogenic hematopoietic stem cell transplants.
 - b) For the diagnosis of sickle cell disease.
 - c) As a routine pre-transfusion test.
 - d) As a routine screen for individuals receiving a solid organ transplant.

NOTES:

Note: For two or more gene tests being run on the same platform, please refer to AHS-R2162 Reimbursement Policy.

IV. Table of Terminology

Term	Definition
AABB	Association for the Advancement of Blood & Biotherapies
ABOi	ABO-incompatible
ASH	American Society of Hematology
BCSH	British Committee for Standards in Hematology
CIBMTR	Center for International Blood and Marrow Transplant Research
CLIA '88	Clinical Laboratory Improvement Amendments Of 1988
CMS	Centers For Medicare and Medicaid Services
DAT	Direct antiglobulin test
DAT+	Direct antiglobulin test positive
EAU	European Association of Urology
EDQM	European Directorate for the Quality of Medicines & HealthCare
FDA	Food and Drug Administration
<i>FUT2</i>	<i>Fucosyltransferase 2</i>
HDFN	Hemolytic disease of the fetus and newborn
HEA	Human erythrocyte antigen
HLA	Human leukocyte antigen
HSCT	Hematopoietic stem cell transplantation
HTR	Hemolytic transfusion reaction
ICTM	International Collaboration for Transfusion Medicine
ISBT	International Society of Blood Transfusion
JPAC	Joint United Kingdom Blood Transfusion and Tissue Transplantation Services Professional Advisory Committee

KDIGO	Kidney disease improving global outcomes
LAMP	Loop-mediated isothermal amplification method
LDT	Laboratory-developed test
MHC	Major histocompatibility complex
MT SC	Molecular testing standards committee
NGS	Next generation sequencing
NHLBI	National Heart, Lung, And Blood Institute
NMDP	National marrow donor program
NTDT	Non-transfusion-dependent thalassemia
PCR	Polymerase chain reaction
PCR-RFLP	Polymerase chain reaction restriction fragment length polymorphism
RBC	Red blood cell
Rh	Rhesus
RT-q	Reverse transcription-quantitative
SCD	Sickle cell disease
SNP	Single-nucleotide polymorphism
SSP-PCR	Sequence-specific polymerase chain reaction
TDT	Transfusion dependent thalassemia
TIF	Thalassemia International Federation

V. Scientific Background

Transfusion medicine requires extensive blood type knowledge to ensure a safe and efficient transfusion process. Blood type differs throughout the population based on an individual’s genome, and genes can vary due to allelic variations. Alleles are alternative forms of the same gene that arise by mutation. Alleles cause genomic changes that ultimately lead to a discrepancy in the proteins produced in the body. Single-nucleotide polymorphisms (SNPs) are also found in the genome and describe a location where the nucleotide that is present differs between individuals because a substitution has been made. Alleles can be caused by SNPs, or other genetic mutations such as additions, deletions, and insertions. SNPs do not always lead to new alleles, as they could occur in non-coding areas of the genome. These alleles and SNPs play an important role in blood type and, therefore, in blood transfusion outcomes. Genetic variations will always affect an organism’s genotype, which is the set of genes carried by the individual’s cells, but may or may not affect an organism’s phenotype, which are the observable characteristics or physical expression of those genes.

Blood Groups

Blood is complex and can be categorized into several groups. Historically, blood groups have been classified by the antigens found “on or in the surface of erythrocytes which are present in certain individuals of a species but are lacking in others.”⁵ These antigens are proteins with the ability to promote an immune response in the body by inducing the formation of antibodies.

As of September 2024, the International Society of Blood Transfusion has recognized 47 blood group systems.⁶ This number is constantly changing as new discoveries are made. Ten years ago, McBean, et

al. (2014) reported that 35 blood group systems had been identified, as well as 44 blood group genes and 1568 alleles. Most of these blood group antigens result from SNPs.³

Karl Landsteiner, an Austrian biologist in the twentieth century, received the Nobel Prize for the discovery of the first human blood grouping system, ABO, in the early 1900s.⁸ The ABO group was later classified into four antigens (A, B, O and AB) and six genotypes (AA, AO, BB, BO, OO and AB) in 1924.⁹ Examples of these are shown below in Table 1. The ABO blood group has three main allelic forms at its chromosomal locus: A, B and O. An individual's ABO blood type is genetically inherited, and A and B alleles are inherited in a codominant manner over O.⁸ The ABO locus has been identified on chromosome 9 at 9q34.1-q34.2; differences in the A and B alleles have been identified and include variations in seven nucleotides via substitution, with four translating into different amino acids.¹⁰

Another inherited antigen found on the surface of red blood cells is the Rhesus (Rh) antigen (+/-); after the ABO blood group, the Rh factor is the most clinically significant factor.¹¹ The Rh blood group system, also identified by Karl Landsteiner alongside Alexander Weiner, was named for the rhesus monkey from which this blood group was discovered.¹² The Rh+ genotype is completely dominant over Rh-. The Rh blood group system is comprised of 54 antigens and is "the most complex and polymorphic system."¹³ Several journal articles have identified genetic variants in the RH (*RHD* and *RHCE*) genes, including SNP substitutions, insertions, deletions, and rearrangements; however, the expression of these variants require further research to determine how overall blood type is affected.¹³ Westhoff (2006) states that more than 100 different *RHD* genes have been identified which encode "proteins with single amino acid changes, or rearranged genes encoding hybrid proteins, and over 50 different *RHCE* genes with single or multiple amino acid changes." Genetic variation in the *RHD* and *RHCE* genes, including partial D antigens, are common, especially in individuals with African descent; further, the weak D phenotype is commonly identified in Caucasians.⁴ Other minor blood group systems include Kell, Kidd, Duffy, MNS, P, Lewis, Junior, and Lutheran.^{13,14}

Red blood cell genotyping is necessary to confirm the presence or absence of Duffy antigens (Fy(a) and Fy(b)) on red blood cells. The Duffy-null phenotype is more common in individuals of African descent and can be associated with resistance to malaria, particularly *Plasmodium vivax*. Genetic variation determines Duffy blood group status, which has impacts that may encompass: (1) malaria resistance, (2) hemolytic transfusion reactions, and (3) hemolytic disease of the fetus and newborn (HDFN). Duffy antigen expression also affects baseline neutrophil counts. However, the Duffy-null phenotype can also be linked to a benign form of neutropenia (i.e., low neutrophil count), which is prevalent in individuals of African ancestry. This condition (known as benign ethnic neutropenia) does not typically result in increased susceptibility to infections.^{15,16} By confirming the Duffy-null phenotype through genotyping, it is possible to differentiate between benign ethnic neutropenia and other causes of neutropenia (that may be cause for heightened concern). Additionally, in transfusion settings, genotyping is essential to ensure compatibility and prevent alloimmunization.¹⁷

Blood Transfusions

Certain antibodies are considered more clinically significant than others for blood transfusion purposes. Clinically significant antibodies (with antigens listed in the subsequent parentheses) include "ABO (A, B), Rh (D, C, c, E, e), Duffy (Fya, Fyb), Kidd (Jka, Jkb), Kell (K, k), and SsU (S, s, U)" and less clinically significant antibodies include "Lewis (Le^a, Le^b), MN, P1, Xg^a, Cartwright (Yt^a), Bg, Knops (Kn^a, McC^a, Yk^a), Chido/Rodgers (Ch1/Rg1), Sda; as well as high titer low avidity (HTLA) antibodies."¹⁸

The ABO blood group is widely accepted as the most important of all blood systems for blood transfusion and transplant purposes. This is because the ABO group is responsible for most immune responses due to blood type incompatibility.¹⁹ Further, ABO is “the only blood group system in which individuals predictably have antibodies in their serum to antigens” absent from their red blood cells.⁸ It is known that individuals with type A blood (containing A antigens) have anti-B antibodies in their serum, individuals with type B blood (containing B antigens) have anti-A antibodies in their serum, individuals with type O blood (containing no antigens) have anti-A and anti-B antibodies in their serum, and individuals with type AB blood (containing A and B antigens) do not have any anti-A or anti-B antibodies in their serum.¹⁰ ABO antibodies form in the serum naturally and are stimulated when the immune system encounters the “missing” ABO blood group antigen from food or in micro-organisms; “This happens at an early age because sugars that are identical to, or very similar to, the ABO blood group antigens are found throughout nature.”¹⁰ Although every red blood cell reportedly expresses about two million ABO blood group antigens, ABO antigens are not only present on red blood cells; these antigens are also found on many types of human tissue and most endothelial and epithelial cells.¹⁰ In certain individuals, these antigens can also be found in saliva and most bodily fluids as well.¹⁰

Table 1: Phenotypes, Genotypes and Antibodies of the ABO Blood Group

Blood Type	Phenotype (i.e. antigen)	Potential Genotype(s)	Antibodies found in serum
A	A	AA, AO	Anti-B
B	B	BB, BO	Anti-A
AB	A and B	AB	None
O	Neither A nor B	OO	Anti-A and Anti-B

Due to the presence of antigens and antibodies on red blood cells, safe blood transfusions rely heavily on blood type knowledge. Administration of the wrong blood type can immediately lead to red blood cell lysis and death, and it is a leading cause of transfusion-related death as reported to the Food and Drug Administration (FDA).⁸ If the incorrect blood type is given to a patient, antibodies begin complement causing “rapid intravascular hemolysis, triggering an acute hemolytic transfusion reaction that can cause disseminated intravascular coagulation, shock, acute renal failure, and death.”¹⁰

Several medical procedures utilize blood antigen typing such as blood transfusions, bone marrow transplants, stem cell transplants, and organ transplants. Blood transfusions may be administered for a multitude of reasons, including severe blood loss, leukemia, sickle cell disease, thalassemia, anemia, and kidney disease. Bone marrow, which is found in several adult bones including those of the pelvis, can assist with the transplant of healthy blood stem cells to replace others that have been destroyed by disease or infection; bone marrow transplants are known to assist in the treatment of several cancers, including leukemia, myeloma and lymphoma.^{20,21} Several factors—including age, illness severity, comorbidities, and hemorrhage amount and rate—should be taken into account before a blood transfusion occurs.^{1,22} Still, it has been reported that the use of blood transfusions for medical practice has been notoriously overused since the 20th century for the treatment of anemia and hemorrhage.²² Based on data distributed by the Red Cross, more than 30 million blood components are transfused annually in the United States.¹ In addition to whole blood transfusions, several types of blood product transfusions are available, including platelet, plasma and cryoprecipitate.²²

Hematopoietic Stem Cell Transplantation (HSCT)

Hematopoietic stem cells are immature cells with the ability to develop into all types of blood cells including red blood cells, white blood cells, and platelets. The transplantation of these cells, known as a hematopoietic stem cell transplantation (HSCT), is a medical procedure which involves the intravenous transfusion of hematopoietic stem cells obtained from the same (autologous) or different (allogenic) individual. These stem cells can be obtained from the umbilical cord, bone marrow, or peripheral blood and may be used to improve hematopoietic function or fight diseases such as leukemias, lymphoid neoplasia, solid tumors, and non-malignant disorders.²³

In contrast to the requirement of ABO match for other types of blood transfusions and solid organ transplants, ABO mismatch is acceptable in HSCTs.²⁴ HSCTs can be safely matched by the human leukocyte antigen (HLA), which is inherited independently of the ABO antigens.^{24,25} Approximately 40-50% of all HSCTs will involve recipient-donor ABO incompatibility.^{25,26} However, an ABO mismatch may cause the recipient to experience pure red blood cell aplasia, delayed hemolytic reactions, or delayed red blood cell engraftment.²⁵ Researchers note that outcomes in ABO-incompatible HSCT have yielded inconsistent results, and pre-transplant antigen evaluation may be important to determine the extent of the incompatibility.^{25,27}

Solid Organ Transplants

Solid Organ transplants are common between blood group- compatible individuals, with this process currently considered the most effective treatment for end-stage organ failure.¹⁹ To date, most important tissues in the body have been successfully transplanted, with exception of the brain.

Solid organ transplant is generally completed with ABO identical donor organs; however, minor ABO-incompatible solid organ transplants may be performed.¹⁸ While ABO compatibility is widely accepted as the primary immunologic barrier for solid organ transplants, HLA compatibility is also very salient.²⁸ The HLA complex is a key part of the immune system controlled by genes on chromosome six; the HLA loci are part of the major histocompatibility complex (MHC) which helps the immune system to recognize foreign molecules.²⁹ Some HLA antigens are recognized on all tissues in the body (as opposed to mainly red blood cells), making these antigens an integral part of organ and tissue transplants. The importance of HLA antibodies have been studied extensively in renal transplants “where recipient antibodies directed against mismatched donor HLA antigens are associated with antibody mediated rejection and/or graft loss.”²⁸

Hemoglobinopathies (Sickle Cell Disease and Thalassemia)

Hemoglobinopathies, such as sickle cell disease and thalassemia, are red blood cell disorders. Sickle cell disease is a collection of inherited blood disorders which cause the development of abnormal sickle-shaped red blood cells that disrupt blood flow and lead to a plethora of problems, including ischemia and inflammation.³⁰ Approximately 300,000 new blood disorder cases are reported globally each year due to sickle cell disease.³¹ Blood transfusions for those with sickle cell disease can assist with an increase in oxygenation to tissues in the body, restoration of blood volume, reduction of sickle erythropoiesis, and prevention of acute vaso-occlusion.³⁰ Alloimmunization, which is when the immune system responds to foreign antigens after a blood transfusion, occurs in a percentage of transfusion cases. “Extended red blood cell (RBC) antigen matching is recommended to limit alloimmunization in patients with sickle cell disease.”³² Thalassemia is an inherited blood disorder in which an abnormal or inadequate amount of hemoglobin is produced. Thalassemia can be categorized as α - or β -thalassemia

depending on which hemoglobin chain is affected.³³ Blood transfusions are a potential treatment option for individuals with this disease.³⁴

Post-transfusion complications are frequent with hemoglobinopathies due to “subtle antigenic differences between donors and patients.”³⁵ For sickle cell disease, red blood cell alloimmunization is common, and red blood cell antigen discrepancies are particularly important to identify because delayed transfusion reactions may be life threatening.³⁰ Regarding thalassemia, alloimmunization rates emphasize “the need for RBC antigen typing before first transfusion and issue of antigen matched blood (at least for Rh and Kell antigen).”³⁴ Patients with sickle cell disease and thalassemia develop alloantibodies at a much higher rate than typical transfusions; patients with diseases such as these, or other patients who receive blood transfusions often, will benefit from an extended phenotype determination either with serological methods or genotypic methods⁴ Fasano and Chou (2016) have used red blood cell antigen genotyping for sickle cell disease, thalassemia and other complications that may arise from transfusions; “Genotyping can be used to determine RBC antigen phenotypes in patients recently transfused or with interfering allo- or autoantibodies, to resolve discrepant serologic typing, and/or when typing antisera are not readily available.”³⁶

Blood Transfusion Molecular Testing

For more than 100 years, agglutination tests using serology have been considered the gold standard for determining blood group antigens.³ These agglutination tests are simple to perform and identify antibodies or antigens in a sample, allowing for blood type to be inferred. Antiglobulin (Coombs) testing is a common laboratory technique that utilizes a secondary antibody to detect antibodies in the patient’s serum; direct antiglobulin testing detects antibodies on the surface of red blood cells, and indirect antiglobulin testing identifies alloantibodies in patient serum.¹⁸ However, these methods have limitations, such as inadequate immunological reagent availability, rising reagent costs, and specificity discrepancies between minor and rare blood types.^{2,3} Further, a recent red blood cell transfusion may also affect serologic results.

Certain immunohematological tests, such as adsorption/elution techniques, enzyme tests and indirect antiglobulin tests, are important for the detection of specific weak D phenotypes, but other weak D phenotypes cannot be detected by serological techniques.³⁷ Weak or partial blood type antigens such as Rh, Fy^b, Jk^a, and U have been known to cause blood typing discrepancies.⁴ Moreover, certain blood type antigens exist for which “there is no commercially available antisera and poorly characterized patient-source antisera (e.g., hrB, hrS, Joa, Hy, U).”⁴ These limitations are significant because researchers have noted that “In practice, serological matching for ABO blood group antigens, Rhesus antigens (RhD, RhC, and RhE), and Kell (K) antigens does not fully prevent alloimmunisation, because of RH alleles with reduced or altered antigen expression.”³⁰

To combat serologic discrepancies, several DNA-based molecular testing methods may now be used for blood transfusion purposes. These methods can resolve the red blood cell inconsistencies often caused by weak and partial antigens.³⁵ Molecular typing is expensive, and results may take a few days or weeks to be returned. For the majority of transfusion recipients, matching beyond ABO and D blood type antigens is not necessary.³⁸ It is, therefore, unlikely that these methods will become a substitute for serological testing but may be used instead when more detailed results are required.³⁹

These molecular techniques include Sanger sequencing of both genomic DNA and complimentary DNA as well as SNP assay testing; an SNP assay may consist of polymerase chain reaction (PCR)-restriction

fragment length polymorphism (PCR-RFLP) or sequence-specific PCR (SSP-PCR).⁴ Additional DNA amplification techniques may also be used for red blood cell genotyping, including “PCR-single-strand conformation polymorphism, allele-specific-PCR, PCR-amplified product length polymorphism, reverse transcription-quantitative (RT-q)PCR and DNA chip.”⁹ Further, next generation sequencing is considered very promising for HLA typing, but more research is required to determine if this method is useful in the identification of blood group antigens.⁴ Other methods include array-based techniques which allow for multi-parallel testing where numerous samples can be searched at once for SNPs or other analytes.⁴ Microarrays, which may be planar arrays or suspended bead arrays, help to overcome several serology limitations by “replacing the immunochemical reagents by synthetic and controlled probes.”³

Genotyping assays from whole-blood samples, which use an on-chip test to identify up to 24 blood group antigens, are also available,³ and next generation sequencing (NGS) methods can detect *de novo* genetic polymorphisms, SNPs, and other genetic variants.³⁵ Liu, et al. (2014) claim that NGS methods “assess genetic variations that cannot be achieved by traditional Sanger sequencing or other genotyping platforms.” More recently, it has been reported that molecular diagnostics for red blood cell genotypes can now be determined in the clinical laboratory and that the majority of allelic variations can be contributed to SNPs.⁴¹

A few panel tests have been developed that identify several blood antigens simultaneously. The BLOODchip® ID CORE XT™ by Grifols Diagnostic Solutions Inc. is an FDA-approved test. The BLOODchip® ID CORE XT™ can simultaneously identify 37 blood antigens in the following ten blood group systems: Rh, Kell, Kidd, Duffy, MNS, Diego, Dombrock, Colton, Cartwright and Lutheran.⁴² This kit will be particularly beneficial to patients who require ongoing blood transfusions, such as individuals with sickle cell disease and thalassemia, as well as for cancer patients who may require very thorough blood typing. This kit uses PCR to amplify DNA samples and can provide results in approximately four hours. A study of 1000 samples reported a sensitivity of 100% and, after bidirectional sequencing, a 100% specificity for the BLOODchip® ID CORE XT blood typing assay; one discrepancy was identified in the E- antigen and 33 discrepancies were identified in the Fy^b- antigen.⁴³

The PreciseType® HEA Test by Immuncor, Inc. is an FDA-approved multiplexed molecular assay which provides information on 35 red blood cell antigens from eleven different blood groups (Rh, Kell, Duffy, Kidd, MNS, Lutheran, Dombrock, Landsteiner-Wiener, Diego, Colton and Scianna).⁴⁴ This test can also identify 24 gene mutations and one SNP commonly associated with hemoglobinopathies. This test uses PCR and requires no confirmation of results with antisera.⁴⁴ Another test by One Lamda, LinkSeq™ Blood Genotyping, was released which is a real-time PCR for RBC, ABO and HPA Genotyping.⁴⁵

There are many other assays not yet FDA-approved but are used for research and investigational purposes only. The chart below displays various blood group genotyping methodologies which detect polymorphisms and antigens.⁴⁶

Name/Manufacturer	Principle	Number of polymorphisms and antigens identified
Immucor PreciseType Molecular BeadChip by BioArray Solutions (FDA approved)	Multiplex PCR followed by hybridization of amplified DNA to probes attached to spectrally distinguishable beads and elongation	24 polymorphisms associated with 38 antigens plus phenotypic variants and Hemoglobin S
BioArray RHCE and RHD BeadChip by BioArray Solutions	Multiplex PCR followed by hybridization of amplified DNA to probes attached to spectrally distinguishable beads and elongation	35+ <i>RHCE</i> variants; 80+ <i>RHD</i> variants
ID CORE XT by Progenika Biopharma (FDA-approved)	Multiplex biotinylating PCR followed by hybridization to probes on color-coded microspheres	29 polymorphisms associated with 37 antigens and phenotypic variants
ID RHD XT by Progenika Biopharma	Multiplex biotinylating PCR followed by hybridization to probes coupled to color-coded microspheres	6 <i>RHD</i> variants and HPA-1
Hemo ID DQS Panel by Agena Bioscience	Multiplex end-point PCR and single base primer extension	101 antigens associated with 16 systems, and 23 platelet and neutrophil antigens, in modules
HIFI Blood 96 by AXO Science	Automated multiplex PCR and microarray-based assay	15 polymorphisms associated with 24 antigens
RBC-FluoGene vERYfy eXtend by inno-train diagnostik GMBH	Automated TaqMan-based assay	70 antigens and phenotypic variants associated with 12 systems
RBC-ReadyGene by inno-train diagnostic GMBH	PCR-SSP-based assay	16 modules encompassing antigens and variant phenotypes within 13 systems
TaqMan genotyping on OpenArray by BioTrove	Nanofluidic TaqMan assays performed in OpenArray plates	16, 32 or 64 assays (custom designed)
Pre-designed TaqMan assays Thermo Fisher Scientific	Real-time allelic discrimination PCR	Polymorphisms associated with eight systems

Analytical Validity

A novel method for ABO genotyping was developed by Muro, et al. (2012) which used allele-specific primers and real-time PCR; this method can be completed in less than two hours, detects SNPs at three different nucleotide positions in the ABO gene, and can determine six main ABO genotypes. The authors state that “this method could be applicable for rapid and simple screening of forensic samples.”⁴⁷ However, this method is limited for transfusion medicinal purposes as it only identifies ABO genotypes.

Zhang, et al. (2015) developed a method of determining ABO blood group genotypes with a real-time loop-mediated isothermal amplification method (LAMP); this LAMP method used two SNPs at nucleotides 261 and 803 to differentiate six ABO genotypes in less than an hour. A total of 101 samples were tested in this study, and each sample resulted in an ABO genotype; “The results were compared with the phenotypes determined by serological assay and the genotypes determined by direct sequencing, and no discrepancies were observed.”⁹ This shows that this LAMP method is an accurate and efficient method to assist in ABO blood type genotyping.

Krog, et al. (2019) have developed 35 PCR assays for blood donor genotyping. This high-throughput PCR genotyping method analyzed samples from 1034 patients, identifying 62 discrepancies between initial results, 43 of which are due to serology techniques.⁴⁸ The accuracy of the genotyping method was determined at 99.9% with only 17 errors; “Of 17 discrepancies caused by the genotype, three were incorrect antigen-negative predictions and could potentially, as the solitary analysis, have caused an adverse transfusion reaction.”⁴⁸ This is an extremely sensitive and cost-efficient method with a high capacity for screening many donors.

Another set of researchers developed a method of amplifying DNA via PCR “directly from plasma or serum of blood donors followed by a melting curve analysis in a capillary rapid-cycle PCR assay.”⁴⁹ This method allows the DNA extraction step to be skipped, permitting this assay to be completed in only 40 minutes. A positive predictive value was identified at 100%, and a negative predictive value at 84%. The authors state that “With fast turnaround times, the rapid-cycle PCR assay may eventually be developed and applied to red cell genotyping in the hospital setting.”⁴⁹

It has been reported that the genetic Rh complexity among sickle cell disease patients is so great that molecular assays are not detailed enough to identify all possible genetic variants; therefore, next generation sequencing has been employed to identify all Rh genetic variants in an effort to improve transfusion outcomes in sickle cell disease patients.⁵⁰ This study used samples from 35 sickle cell disease patients with “unexplained Rh antibodies”; a genotypic method which used *RHD* and *RHCE* gene-specific primers was compared to traditional serological data. It was reported that “Ten and 25 variant *RHD* and *RHCE* alleles were identified, respectively. Among all cases of unexplained Rh antibodies, 62% had been inaccurately classified by serological analysis and, of these, 73.1% were considered as relevant.”⁵⁰ This next generation sequencing assay is therefore an effective measure to identify genetic variants and improve blood transfusion outcomes in the sickle cell disease population.

Molecular *RHD* typing was implemented at two institutions in Europe via PCR-SSP; this was completed to assist in blood transfusion cases.³⁷ This molecular method confirmed the majority of serologically identified weak D variants with more detail, and it also identified a discrepancy in one sample.³⁷ This study has verified the accuracy of this genotyping method to confirm *RHD* variants, which will assist in the implementation of safer blood transfusion practices.

Shah, et al. (2019) compared serological and molecular detection methods for common red cell antigen groups in thalassemia major and sickle cell disease patients. Specifically, the authors compared the molecular genotyping of Rh (D, C, c, E, e), Kell (K, k), Duffy (Fy^a, Fy^b) and Kidd (Jk^a, Jk^b) blood group antigens using PCR and PCR-RFLP to red blood cell antigen phenotypes identified by serology; serological testing was completed by tube agglutination. The authors note that the serological testing for extended RHCcEe, Kell, Kidd and Duffy testing for multi-transfused patients may not generate the correct blood grouping of the recipient. The authors report that “In more than 80% of the cases recipient's molecular testing blood groups were at variance with serologically tested blood groups ($p < 0.0001$). Mixed field

reactions in serological typing were common. In sickle cell anemia patients, no discrepancy was found.”⁵¹ This shows that molecular detection methods to determine the genotype was particularly useful in multi-transfused thalassemia patients.

Sheppard, et al. (2020) investigated the diagnostic accuracy of two PCR-based group genotyping platforms for patients with sickle cell disease (SCD) including the human erythrocyte antigen (HEA) BeadChip (Immucor, Norcross, GA) and ID CORE XT (Progenika-Grifols, Barcelona, Spain). DNA samples were extracted from 138 patients with SCD to compare predicted phenotype results and calculate a concordance rate. As a result, predicted phenotype results were comparable across platforms for 31 antigens and the concordance rate was 99.9%. The study also identified discrepancies between the two assays in the highly variable Rh blood group system. In some cases, the two assays interrogated different positions in the gene, and the software made different assumptions based on the population frequency of the alleles. The ID CORE XT was able to identify the phenotype in two of three samples which had discrepancies in the Rh blood group while the HEA BeadChip identified the phenotype in one of three samples due to lack of interrogation in the gene. The authors conclude that genotyping provides valuable information not available by serologic methods and both methods are beneficial due to the high concordance rate.⁵²

Jadhao, et al. (2022) studied the use of RBCeq, an algorithm for accurate genetic blood typing which identifies 36 blood group systems. "The RBCeq algorithm demonstrated 99.07% concordance when validated on 402 samples which included 29 antigens with serology and nine antigens with SNP-array validation in 14 blood group systems and 59 antigens validation on manual predicted phenotype from variant call files." The authors conclude that the use of RBCeq can reduce pre-transfusion testing time and increase sample processing throughput.⁵³

Clinical Utility and Validity

It is imperative that patients with sickle cell anemia receive correct red blood cell transfusions. In an effort to compare the accuracy of new DNA-based testing methods to traditional agglutination methods, Casas, et al. (2015) compared 494 red blood cell phenotypes of sickle cell disease patients determined by hemagglutination methods to genotypic predictions made by DNA-based testing methods. If any discrepancies were identified, repeat serologic testing was performed to confirm these results. It was found that “Seventy-one typing discrepancies were identified among 6360 antigen comparisons (1.1%). New specimens for repeat serologic testing were obtained for 66 discrepancies and retyping agreed with the genotype in 64 cases.”³² This shows that DNA-based red blood cell genotyping can provide more accurate results when compared to traditional serologic methods, leading to more safe and efficient treatments for sickle cell disease patients.

Flegel, et al. (2015) completed a large-scale blood genotyping project; samples were analyzed from 43,066 blood donors from the Blood Center of Wisconsin. Red blood cell genotyping was completed with “a nanofluidic microarray system, using 32 single nucleotide polymorphisms to predict 42 blood group antigens.”⁵⁴ This microarray technique allowed researchers to fill 95% of antigen-negative red blood cell requests for hospitals served by the Blood Center of Wisconsin; the remaining requests were filled via serology identification. This genotyping system is therefore efficient and should be used along with conventional serology methods.

The frequency of red blood cell autoimmunization and alloimmunization development in β -thalassemia major patients was studied by Dhawan, et al. (2014); clinical and transfusion records from 319 patients

were analyzed. A total of 18 patients were found to have alloantibodies, 90 patients developed autoantibodies, and nine patients had both alloantibodies and autoantibodies; “Alloimmunization was detected in 5.64% of multitransfused thalassemia patients. Rh and Kell blood group system antibodies accounted for more than 80% of alloantibodies. This study re-emphasizes the need for RBC antigen typing before first transfusion and issue of antigen matched blood (at least for Rh and Kell antigen).”³⁴

Parkhideh, et al. (2019) studied the effects of ABO incompatibility on the outcome of allogenic HSCTs. This retrospective study includes data from 186 different patients with 108 identical, 38 minor, 32 major and eight bidirectional ABO incompatible scenarios. The researchers did not identify any significant associations between ABO incompatibility and white blood cell or platelet engraftment, or graft-versus-host disease; however, white blood cell engraftment was significantly lower in patients with minor ABO incompatibilities.²⁷

Shih, et al. (2020) discussed using red cell antigen genotyping and serological phenotyping in SCD patients to risk-stratify patients for alloimmunization risk. In this study, 106 SCD patients underwent genotyping to assess whether partial antigen expression may lead to increased risk of alloimmunization and hemolytic transfusion reactions (HTRs). A total of 91% of the 106 patients showed additional clinically relevant genotyping information when compared to serological phenotyping alone. The FY*02N.01 was found in 90% of patients and RH variant alleles were found in 49% of patients, with most of them having putative partial antigen expression. Overall, genotyping helped discover more clinically relevant information and “genotyping SCD patients before transfusion may prevent alloimmunization and HTRs.” Additionally, “knowledge of the FY*02N.01 variant allele increases feasibility of finding compatible blood.”⁵⁵

Vege, et al. (2021) studied the impact of *RHD* genotyping on transfusion practice and identification of novel *RHD* alleles. A total of 57 samples from Denmark and 353 samples from the US were genotyped with *RHD* Beadchip in the US and CDE in Denmark. “Of Caucasian samples from Denmark, 90% (n = 51) had weak D types 1, 2, or 3; two had other weak D, two partial D, and two new alleles. In diverse ethnic U.S. samples, 44% (n = 155) had weak D types 1, 2, or 3 and 56% (n = 198) had other alleles. Most samples with weak or variable D typing from Denmark had alleles without risk for anti-D. In U.S. samples, 48% could safely be treated as D+, 18% may require consideration if pregnancy possible, and 34% could potentially benefit from being treated as D.”⁵⁶

VI. Guidelines and Recommendations

The Association for the Advancement of Blood & Biotherapies (AABB) and The Molecular Testing Standards Committee (MT SC)

The second edition of the MT SC for red cell, platelet and neutrophil antigen guidelines states that “When a serological reagent is not available, molecular results shall be confirmed by another method (e.g., DNA sequencing) or an external laboratory.” The seventh edition, published in 2024, does not include any relevant recommendations for molecular testing.⁵⁷ This committee is spearheaded by the AABB (formerly known as the American Association of Blood Banks).

American Society of Hematology (ASH)

The ASH has published guidelines for sickle cell disease transfusion support. These guidelines give the following recommendations:

- “The ASH guideline panel suggests an extended red cell antigen profile by genotype or serology over only ABO/RhD typing for all patients with SCD (all genotypes) at the earliest opportunity (optimally before the first transfusion) (conditional recommendation based on very low certainty in the evidence about effects).
- The ASH guideline panel recommends prophylactic red cell antigen matching for Rh (C, E or C/c, E/e) and K antigens over only ABO/RhD matching for patients with SCD (all genotypes) receiving transfusions (strong recommendation based on moderate certainty in the evidence about effects).”⁵⁸

British Committee for Standards in Hematology (BCSH)

The BCSH has published guidelines on pre-transfusion compatibility procedures in blood transfusion laboratories. These guidelines state the following:

“If a patient shows signs of active haemolysis following transfusion but no antibodies are detectable and no other possible cause is known (e.g. sickle cell crisis or mechanical haemolysis due to heart valve failure), this can be due to very rare examples of antibodies which are not detectable by normal serological techniques. In this case:

- i. Serological investigation should be undertaken using more sensitive techniques such as Polyethylene Glycol or enzyme IAT, which may require referral to a reference center.
- ii. It may be appropriate to fully red cell genotype the patient and select donor blood matched as closely as possible.
- iii. Advice should be sought from a clinical haematologist or from a reference laboratory at the local Blood Centre.”⁵⁹

Regarding antibody screening, the BCSH states that “Antibody screening should always be performed as part of pre-transfusion testing as it provides the laboratory with a more reliable and sensitive method of detecting a red cell antibody than serological crossmatching.”⁵⁹

For patients who have received a transfusion in the previous three months, the BCSH recommends:

- i. “Phenotyping may be misleading due to the presence of transfused cells; In this case genotyping can be used as an alternative and is available from specialist laboratories.
- ii. When an Rh antibody is suspected, the C, c, E, e types should be determined to aid in the selection of appropriately phenotyped red cells.
- iii. Where antibody exclusion is problematic, more extensive phenotyping may be informative to identify antigens to which the patient may be alloimmunised.”⁵⁹

For patients with autoimmune hemolytic anemia, BCSH guidelines state that the “Risk of transfusion reaction due to underlying alloantibodies can further be reduced by matching blood with the patient's own type. Determination of the phenotype in multiply transfused and/or DAT+ patients may be problematic and determination of genotype offers useful information in managing these complex cases; this particularly applies to regularly transfused cases and those with autoantibodies resistant to removal by adsorption.”⁵⁹

Finally, for patients with sickle cell disease, the BCSH recommends the following:

“The patient’s red cells should be phenotyped as fully as possible prior to transfusion. Where patients have already been transfused, the genotype can be determined.

- i. An extended phenotype (or genotype) should include C, c, E, e, K, k, Jka, Jkb, Fya, Fyb, S, s.
- ii. If S- s-, then U typing should be performed.
- iii. As a minimum, red cells should be matched for Rh and K antigens.”⁵⁹

The BCSH also published guidelines on red blood cell transfusion in sickle cell disease. The following recommendations are given for investigating a hemolytic transfusion reaction:

“Serological testing on pre-transfusion and post-transfusion blood samples.

- Repeat ABO/Rh D typing
- Check antibody screen on both samples
- Red cell units transfused within 12–24 h should be crossmatched against both the pre- and post-reaction samples
- Check the direct antiglobulin test (DAT). A positive DAT may be encountered as part of an investigation

Selection of red cell units for further transfusion

- Select ABO extended Rh and K matched units negative for the relevant antigen(s) to which there are current or historical antibodies
- Undertake serological crossmatch to check compatibility; electronic issue should not be used
- If the identity of the new alloantibody is in doubt despite further specialist testing, consider providing extended antigen matched blood (if serological phenotyping cannot be used because of the presence of transfused donor red blood cells, the sample should be sent to an appropriate reference laboratory for molecular red cell genotyping).”⁶⁰

These guidelines later stated that “Fetal RHD typing using a high-throughput methodology in pregnant [individuals] who have not formed anti-D, as part of a screening program to target anti-D Ig prophylaxis, is sufficiently accurate for implementation from 11 weeks gestation. The cost effectiveness of such testing is dependent on provision at a point in the antenatal care pathway that does not necessitate an additional visit (Grade 1C).”⁶¹

Regarding serological methods, the guidelines state that samples from pregnant individuals “with immune anti-D or anti-c should be assessed serologically at 4 weekly intervals to 28 weeks gestation and at fortnightly intervals thereafter until delivery. Such cases should be referred to a fetal medicine specialist if the antibody reaches the critical level and/or the level is rising significantly, where assessment of the need for further monitoring will be made (Grade 1B)” and pregnant individuals “with anti-K or other Kell system antibodies (unless the father is confirmed to be negative for the corresponding antigen) should be assessed serologically at monthly intervals to 28 weeks gestation and at fortnightly intervals thereafter until delivery and referred to a fetal medicine specialist when the antibody is first identified (Grade 1B).”⁶¹

The BCSH states that “A record of the pregnant woman’s ABO and D type performed at booking is useful as confirmation of any subsequent testing performed on another sample taken at the point of need, should the woman or her baby require blood transfusion at a later date.” Therefore, the BCSH

recommends: “ABO and D grouping should be performed in accordance with the guidelines for compatibility procedures in blood transfusion laboratories. If clear-cut positive results are not obtained in D typing, the woman should be classified as D negative until the D status is confirmed. All pregnant women confirmed to be D negative should be given written information about their D-negative status and the importance of anti-D Ig prophylaxis if the foetus is predicted to be D positive by cell free foetal DNA (cffDNA), or if the foetal D type is unknown. Their D status should be clearly recorded in the notes to inform those responsible for their care of the need to offer prophylactic anti-D Ig².”⁶²

European Directorate for the Quality of Medicines & HealthCare (EDQM)

The EDQM has published a guide for the preparation, use and quality assurance of blood components. Regarding blood group testing for donor blood, it is stated that “Each donation should be tested for ABO and RhD blood groups and at least all first-time donors should be tested for clinically-significant irregular red-cell antibodies” and that “ABO and RhD blood groups should be verified on each subsequent donation.”⁶³ The guidelines also give laboratory testing steps for both serological and NAT testing.

The EDQM also recommends that serological testing is the standard procedure used in most laboratories and “molecular testing is becoming increasingly available and used as an alternate or supplemental technique to serological testing. In time, molecular testing may replace the need for routine serological testing.” Molecular testing should be performed when the results of serological testing of blood donors and patients are unclear, when there is a suspicion of weak antigens or variants, or when serological reagents directed to specific antigens do not exist or are not readily available. “It can also be useful in chronically transfused patients to predict their red cell phenotype and aid the selection of phenotyped or genotyped red cell components. Testing can be undertaken on samples from blood, amniocentesis, biopsy of chorionic villi, and plasma.”⁶³

International Collaboration for Transfusion Medicine (ICTM)

The ICTM published red blood cell related guidelines for patients with hemoglobinopathies. These background of these guidelines state that “No international consensus exists for antigen matching in patients with SCD and b-thalassemia. Some transfusion medicine services provide preventive phenotype (or genotype) extensive matching for C, c, E, e, and K antigens in addition to routine ABO and D. Additional extended matching for Jka, Jkb, Fya, Fyb, and S, s is offered at some centers. In contrast, others provide ABO and D matched RBCs and switch to more extensive matching only if alloantibodies are detected.”⁶⁴

The following recommendations were given by the ICTM:

- “Patients with SCD who do not have alloantibodies and who are anticipated to have a transfusion (simple or exchange transfusion) should probably be transfused with CcEe and K-matched RBCs to reduce the risk of alloimmunization (low quality of evidence, weak recommendation). RBCs matched for CcEe and K can be provided by phenotyping or genotyping RBCs. The use of phenotyping or genotyping will depend on the costs of each method in each jurisdiction. Genotyping appears to be more accurate.
- Patients with thalassemia syndromes who do not have alloantibodies and who require RBC transfusion should probably be transfused with CcEe and K-matched RBCs to reduce the risk of alloimmunization (low quality of evidence, weak recommendation). RBCs matched for CcEe and K can be provided by phenotyping or genotyping RBCs. The use of phenotyping or genotyping will

depend on the costs of each method in each jurisdiction. Genotyping appears to be more accurate.”⁶⁴

In 2020, the British Journal of Haematology released a position paper reviewing ICTMG guidelines and were in agreement with the above recommendations.⁶⁵

National Heart, Lung, and Blood Institute (NHLBI)

An expert panel from the NHLBI state that “RBC units that are to be transfused to individuals with SCD should include matching for C, E, and K antigens.”⁶⁶ The laboratory method to perform the antigen matching is not mentioned in these guidelines.

Thalassemia International Federation (TIF)

The TIF published guidelines for the management of non-transfusion dependent thalassemia (NTDT).⁶⁷ These guidelines recommend that pregnant individuals “with NTDT who were previously never- or minimally-transfused, should be considered at high risk of alloimmunization if blood transfusions are to be administered during pregnancy. If blood transfusion is deemed necessary, extended genotype and antibody screening should be performed before giving any transfusion and fully-phenotyped matched blood should be given.”⁶⁷

The TIF also published guidelines for the management of transfusion dependent thalassemia (TDT) in 2014 which was updated in 2021.^{68,69} These guidelines recommend the following for compatibility testing:

“Before embarking on transfusion therapy, patients should have extended red cell antigen typing that includes at least C, c, D, E, e, and Kell, (though preferably a full red cell phenotype/genotype panel) in order to help identify and characterize antibodies in case of later immunization.

If the patient is already transfused, antigen typing can be performed using molecular rather than serologic testing.

All patients with thalassaemia should be transfused with ABO and Rh(C, c, D, E, e) and Kell compatible blood in order to avoid alloimmunisation against these antigens.

There should be a valid group and antibody screen available prior to transfusion being administered.

At each transfusion, give ABO, Rh(D) compatible blood. Choosing units compatible units for ABO, C,c, E,e and Kell antigens is highly recommended.

Before each transfusion, perform a screen for new antibodies and an IAT cross-match, or in centres that meet regulatory requirements, perform an electronic cross-match where allowed.”⁶⁹

In the guidelines for transfusion-dependent β -Thalassemia, TIF recommends: “Before the first transfusion, perform extended red cell antigen typing of patients at least for Rh C, c, D, E, e and Kell (K, k), and if available a full red cell pheno/genotype.”⁷⁰

European Association of Urology (EAU)

The EAU updated their guidelines on renal transplantation in 2024. These guidelines include the following strong recommendations:

- “Determine the ABO blood group and the human leukocyte antigen A, B, C and DR phenotypes for all candidates awaiting kidney transplantation.
- Test both the donor and recipient for human leukocyte antigen DQ. Human leukocyte antigen DP testing may be performed for sensitised patients.
- Perform thorough testing for HLA antibodies before transplantation
- Perform adequate cross-match tests to avoid hyper-acute rejection, before each kidney and combined kidney/pancreas transplantation
- Prevent hyper-acute rejection by adequate ABO blood group and HLA matching of donor and recipients.”⁷¹

The article also states that “compatibility for ABO blood group antigens and HLA antigens was of critical importance in kidney transplantation. This may change in the future, e.g. in the new U.S. allocation system A2 and A2B donors are transplanted into B recipients. To avoid an increasing imbalance between demand and supply in deceased-donor kidney transplantation in O recipients, ABO identity is demanded by several organ allocation organisations with a few exceptions, e.g. as in zero HLA-A+B+DR-mismatch kidneys. With the introduction of antibody elimination methods, potent immunosuppression and novel agents (e.g. anti B-cell drugs), successful ABO-incompatible living donor transplantations, with good long-term outcomes are possible.”⁷¹ ABO genotyping is not mentioned in these guidelines.

Kidney Disease Improving Global Outcomes (KDIGO)

The KDIGO published guidelines on the evaluation and care of living kidney donors. The following recommendations were given:

- “Donor ABO blood typing should be performed twice before donation to reduce the risk of unintended blood type incompatible transplantation.
- Human leukocyte antigen (HLA) typing for major histocompatibility complex (MHC) Class I (A, B, C) and Class II (DP, DQ, DR) should be performed in donor candidates and their intended recipients, and donor-specific anti-HLA antibodies should be assessed in intended recipients
- Donor candidates who are ABO blood group or HLA incompatible with their intended recipient should be informed of availability, risks, and benefits of treatment options, including kidney paired donation and incompatibility management strategies.”⁷²

The guidelines also mention in a rationale section that “ABO blood typing should be performed in living donor candidates before donation, including routine duplicate testing, to reduce the risk of unintended blood type-incompatible transplantation. Unintended ABO-incompatible (ABOi) transplantation should be avoidable with ABO typing of the donor and the recipient; however, human errors have led to cases of accidental ABOi organ transplantation in contemporary practice. ABO-subtype testing should be performed when donation is planned to recipients with anti-A antibodies.”⁷²

The authors later state that “While recipient care is out of the scope of this guideline, it is important to emphasize that recipient candidates should undergo antidonor antibody examinations, including complement-dependent cytotoxicity or flow cytometry crossmatching and Luminex (Bio-Rad Laboratories, Inc., Hercules, CA) assays to determine the history of sensitization, and this testing should be current before proceeding with donor nephrectomy and living donor transplantation.”⁷²

Eurotransplant Manual

Version 5.4 (Chapter 10) of the Eurotransplant Manual states that “In case of stem cell transplantation before organ transplantation, a new HLA typing and ABO blood group typing should be performed.” The specific methodology is not mentioned.⁷³

National Marrow Donor Program (NMDP) and Center for International Blood and Marrow Transplant Research (CIBMTR)

The NMDP and CIBMTR have published guidelines on unrelated donors and cord blood units for HSCTs. These guidelines state that “Sufficient high-resolution donor-recipient HLA match is of primary importance in transplantation with adult unrelated donors”; further, “While HLA matching remains the primary criteria for donor selection, non-HLA factors are often considered when selecting donors, including cytomegalovirus serostatus, sex, age, ABO compatibility, prior pregnancies, and larger body weight.”⁷⁴

American Red Cross

The American Red Cross published transfusion practice guidelines in 2021. They recommended RHD genotyping be used in individuals of childbearing potential to resolve serologic weak D phenotypes, or discrepant D types and that extended RBC phenotyping (i.e. C/c, E/e, K, Jka/Jkb, Fya/Fyb, M/N, and S/s) be performed routinely on all SCD patients by either serologic or molecular methods.⁷⁵

Joint United Kingdom Blood Transfusion and Tissue Transplantation Services Professional Advisory Committee (JPAC)

The JPAC states that “Genotyping is useful in resolving grouping problems, particularly weak and partial D types.” For the resolution of anomalous grouping during pre-transfusion testing, “Genotyping alone must not be used to determine the ABO group for use in selection of blood for transfusion. Where the patient ABO group cannot confidently be assigned by serology, group O (high-titre negative) blood must be selected.” For the management of patients with autoantibodies, “In patients who cannot be grouped by conventional serology, due to sensitisation of red cells or previous transfusion, genotyping offers a solution.” For the management of patients on therapeutic monoclonal antibodies, “extended phenotyping/genotyping for C, c, E, e, K, (k if K+), MNSs, Jk, Jk, Fy and Fy a b a b (genotyping to be used if the patient has been recently transfused, <3 months ago)” before starting therapeutic monoclonal antibody therapy.⁷⁶

VII. Applicable State and Federal Regulations

DISCLAIMER: If there is a conflict between this Policy and any relevant, applicable government policy for a particular member [e.g., Local Coverage Determinations (LCDs) or National Coverage Determinations (NCDs) for Medicare and/or state coverage for Medicaid], then the government policy will be used to make the determination. For the most up-to-date Medicare policies and coverage, please visit the Medicare search website: <https://www.cms.gov/medicare-coverage-database/search.aspx>. For the most up-to-date Medicaid policies and coverage, visit the applicable state Medicaid website.

Food and Drug Administration (FDA)

Many labs have developed specific tests that they must validate and perform in house. These laboratory-developed tests (LDTs) are regulated by the Centers for Medicare and Medicaid (CMS) as high-complexity tests under the Clinical Laboratory Improvement Amendments of 1988 (CLIA '88). LDTs are

not approved or cleared by the U. S. Food and Drug Administration; however, FDA clearance or approval is not currently required for clinical use.

The Immucor PreciseType Human Erythrocyte Antigen Molecular BeadChip Test

This test was approved by the FDA in 2014 and is an in vitro diagnostic test that is able to molecularly determine allele variants which assist in the prediction of erythrocyte antigen phenotypes.⁷⁷ This test is known as the first FDA approved device for molecular typing of red blood cells.

ID CORE XT by Progenika Biopharma

This molecular based assay tests for non-ABO red blood cell types. This is a PCR hybridization-based genotyping test and can identify alleles which encode for human erythrocyte antigens in DNA and was approved by the FDA in 2018.⁷⁸

VIII. Applicable CPT/HCPCS Procedure Codes

CPT	Code Description
81403	Molecular pathology procedure, Level 4 (eg, analysis of single exon by DNA sequence analysis, analysis of >10 amplicons using multiplex PCR in 2 or more independent reactions, mutation scanning or duplication/deletion variants of 2-5 exons)
81479	Unlisted molecular pathology procedure
0001U	Red blood cell antigen typing, DNA, human erythrocyte antigen gene analysis of 35 antigens from 11 blood groups, utilizing whole blood, common RBC alleles reported Proprietary test: PreciseType® HEA Test Lab/Manufacturer: Immucor, Inc
0084U	Red blood cell antigen typing, DNA, genotyping of 10 blood groups with phenotype prediction of 37 red blood cell antigens Proprietary test: BLOODchip® ID CORE XT™ Lab/Manufacturer: Grifols Diagnostic Solutions Inc.
0180U	Red cell antigen (ABO blood group) genotyping (ABO), gene analysis Sanger/chain termination/conventional sequencing, ABO (ABO, alpha 1-3-N-acetylgalactosaminyltransferase and alpha 1-3-galactosyltransferase) gene, including subtyping, 7 exons Proprietary test: Navigator ABO Sequencing Lab/Manufacturer: Grifols Immunohematology Center
0181U	Red cell antigen (Colton blood group) genotyping (CO), gene analysis, AQP1 (aquaporin 1 [Colton blood group]) exon 1 Proprietary test: Navigator CO Sequencing Lab/Manufacturer: Grifols Immunohematology Center
0182U	Red cell antigen (Cromer blood group) genotyping (CROM), gene analysis, CD55 (CD55 molecule [Cromer blood group]) exons 1-10 Proprietary test: Navigator CROM Sequencing Lab/Manufacturer: Grifols Immunohematology Center
0183U	Red cell antigen (Diego blood group) genotyping (DI), gene analysis, SLC4A1 (solute carrier family 4 member 1 [Diego blood group]) exon 19 Proprietary test: Navigator DI Sequencing Lab/Manufacturer: Grifols Immunohematology Center

CPT	Code Description
0184U	Red cell antigen (Dombrock blood group) genotyping (DO), gene analysis, ART4 (ADP-ribosyltransferase 4 [Dombrock blood group]) exon 2 Proprietary test: Navigator DO Sequencing Lab/Manufacturer: Grifols Immunohematology Center
0185U	Red cell antigen (H blood group) genotyping (FUT1), gene analysis, FUT1 (fucosyltransferase 1 [H blood group]) exon 4 Proprietary test: Navigator FUT1 Sequencing Lab/Manufacturer: Grifols Immunohematology Center
0186U	Red cell antigen (H blood group) genotyping (FUT2), gene analysis, FUT2 (fucosyltransferase 2) exon 2 Proprietary test: Navigator FUT2 Sequencing Lab/Manufacturer: Grifols Immunohematology Center
0187U	Red cell antigen (Duffy blood group) genotyping (FY), gene analysis, ACKR1 (atypical chemokine receptor 1 [Duffy blood group]) exons 1-2 Proprietary test: Navigator FY Sequencing Lab/Manufacturer: Grifols Immunohematology Center
0188U	Red cell antigen (Gerbich blood group) genotyping (GE), gene analysis, GYPC (glycophorin C [Gerbich blood group]) exons 1-4 Proprietary test: Navigator GE Sequencing Lab/Manufacturer: Grifols Immunohematology Center
0189U	Red cell antigen (MNS blood group) genotyping (GYPA), gene analysis, GYPA (glycophorin A [MNS blood group]) introns 1, 5, exon 2 Proprietary test: Navigator GYPA Sequencing Lab/Manufacturer: Grifols Immunohematology Center
0190U	Red cell antigen (MNS blood group) genotyping (GYPB), gene analysis, GYPB (glycophorin B [MNS blood group]) introns 1, 5, pseudoexon 3 Proprietary test: Navigator GYPB Sequencing Lab/Manufacturer: Grifols Immunohematology Center
0191U	Red cell antigen (Indian blood group) genotyping (IN), gene analysis, CD44 (CD44 molecule [Indian blood group]) exons 2, 3, 6 Proprietary test: Navigator IN Sequencing Lab/Manufacturer: Grifols Immunohematology Center
0192U	Red cell antigen (Kidd blood group) genotyping (JK), gene analysis, SLC14A1 (solute carrier family 14 member 1 [Kidd blood group]) gene promoter, exon 9 Proprietary test: Navigator JK Sequencing Lab/Manufacturer: Grifols Immunohematology Center
0193U	Red cell antigen (JR blood group) genotyping (JR), gene analysis, ABCG2 (ATP binding cassette subfamily G member 2 [Junior blood group]) exons 2-26 Proprietary test: Navigator JR Sequencing Lab/Manufacturer: Grifols Immunohematology Center
0194U	Red cell antigen (Kell blood group) genotyping (KEL), gene analysis, KEL (Kell metallo-endopeptidase [Kell blood group]) exon 8 Proprietary test: Navigator KEL Sequencing Lab/Manufacturer: Grifols Immunohematology Center

CPT	Code Description
0195U	KLF1 (Kruppel-like factor 1), targeted sequencing (ie, exon 13) Proprietary test: Navigator KLF1 Sequencing Lab/Manufacturer: Grifols Immunohematology Center
0196U	Red cell antigen (Lutheran blood group) genotyping ³ , gene analysis, BCAM (basal cell adhesion molecule [Lutheran blood group]) exon 3 Proprietary test: Navigator LU Sequencing Lab/Manufacturer: Grifols Immunohematology Center
0197U	Red cell antigen (Landsteiner-Wiener blood group) genotyping (LW), gene analysis, ICAM4 (intercellular adhesion molecule 4 [Landsteiner-Wiener blood group]) exon 1 Proprietary test: Navigator LW Sequencing Lab/Manufacturer: Grifols Immunohematology Center
0198U	Red cell antigen (RH blood group) genotyping (RHD and RHCE), gene analysis Sanger/chain termination/conventional sequencing, RHD (Rh blood group D antigen) exons 1-10 and RHCE (Rh blood group CcEe antigens) exon 5 Proprietary test: Navigator RHD/CE Sequencing Lab/Manufacturer: Grifols Immunohematology Center
0199U	Red cell antigen (Scianna blood group) genotyping (SC), gene analysis, ERMAP (erythroblast membrane associated protein [Scianna blood group]) exons 4, 12 Proprietary test: Navigator SC Sequencing Lab/Manufacturer: Grifols Immunohematology Center
0200U	Red cell antigen (Kx blood group) genotyping (XK), gene analysis, XK (X-linked Kx blood group) exons 1-3 Proprietary test: Navigator XK Sequencing Lab/Manufacturer: Grifols Immunohematology Center
0201U	Red cell antigen (Yt blood group) genotyping (YT), gene analysis, ACHE (acetylcholinesterase [Cartwright blood group]) exon 2 Proprietary test: Navigator YT Sequencing Lab/Manufacturer: Grifols Immunohematology Center
0221U	Red cell antigen (ABO blood group) genotyping (ABO), gene analysis, next-generation sequencing, ABO (ABO, alpha 1-3-N-acetylgalactosaminyltransferase and alpha 1-3-galactosyltransferase) gene Proprietary test: Navigator ABO Blood Group NGS Lab/Manufacturer: Grifols Immunohematology Center
0222U	Red cell antigen (RH blood group) genotyping (RHD and RHCE), gene analysis, next-generation sequencing, RH proximal promoter, exons 1-10, portions of introns 2-3 Proprietary test: Navigator Rh Blood Group NGS Lab/Manufacturer: Grifols Immunohematology Center
0246U	Red blood cell antigen typing, DNA, genotyping of at least 16 blood groups with phenotype prediction of at least 51 red blood cell antigens Proprietary test: PrecisionBlood™ Lab/Manufacturer: San Diego Blood Bank
0282U	Red blood cell antigen typing, DNA, genotyping of 12 blood group system genes to predict 44 red blood cell antigen phenotypes Proprietary test: Versiti™ Red Cell Genotyping Panel Lab/Manufacturer: Versiti™ Comprehensive Bleeding Disorder Panel

Current Procedural Terminology© American Medical Association. All Rights reserved.

Procedure codes appearing in Medical Policy documents are included only as a general reference tool for each policy. They may not be all-inclusive.

IX. Evidence-based Scientific References

1. Osterman JL, Arora S. Blood Product Transfusions and Reactions. *Hematol Oncol Clin North Am*. Dec 2017;31(6):1159-1170. doi:10.1016/j.hoc.2017.08.014
2. Westhoff CM. Molecular testing for transfusion medicine. *Curr Opin Hematol*. Nov 2006;13(6):471-5. doi:10.1097/01.moh.0000245695.77758.3d
3. Boccoz SA, Le Goff G, Blum LJ, Marquette CA. Microarrays in blood group genotyping. *Methods Mol Biol*. 2015;1310:105-13. doi:10.1007/978-1-4939-2690-9_9
4. Elite. RBC Genotyping - Elite Healthcare. <https://www.elitecme.com/resource-center/laboratory/rbc-genotyping/>
5. Kabat E. *Blood Group Substances: Their Chemistry and Immunochemistry*. Academic Press Inc. Publishers; 1956.
6. ISBT. Table of blood group systems. <https://www.isbtweb.org/resource/tableofbloodgroupsystems.html>
7. McBean RS, Hyland CA, Flower RL. Approaches to determination of a full profile of blood group genotypes: single nucleotide variant mapping and massively parallel sequencing. *Comput Struct Biotechnol J*. Sep 2014;11(19):147-51. doi:10.1016/j.csbj.2014.09.009
8. Harmening DM, Forneris G, Tubby BJ. *Modern Blood Banking & Transfusion Practices*. Sixth ed. F.A. Davis Company; 2012.
9. Zhang C, Zhu J, Yang J, Wan Y, Ma T, Cui Y. Determination of ABO blood group genotypes using the real-time loop-mediated isothermal amplification method. *Molecular Medicine Reports*. 2015;12:5963–5966.
10. Bethesda DL. *Blood Groups and Red Cell Antigens* 2005.
11. Písačka M. After 70 years, serological RhD determination remains a challenge: DNA to the rescue. *ISBT Science Series*. 2018;doi:10.1111/voxs.12475
12. Agre P, Smith BL, Hartel-Schenk S. Biochemistry of the erythrocyte Rh polypeptides: a review. *Yale J Biol Med*. Sep-Oct 1990;63(5):461-7.
13. Raud L, Ferec C, Fichou Y. From genetic variability to phenotypic expression of blood group systems. *Transfus Clin Biol*. Nov 2017;24(4):472-475. doi:10.1016/j.tracli.2017.06.011
14. Kahar MA, Patel RD. Phenotype frequencies of blood group systems (Rh, Kell, Kidd, Duffy, MNS, P, Lewis, and Lutheran) in blood donors of south Gujarat, India. *Asian J Transfus Sci*. Jan 2014;8(1):51-5. doi:10.4103/0973-6247.126693
15. Merz LE, Story CM, Osei MA, et al. Absolute neutrophil count by Duffy status among healthy Black and African American adults. *Blood Adv*. Feb 14 2023;7(3):317-320. doi:10.1182/bloodadvances.2022007679
16. Merz LE, Achebe M. When non-Whiteness becomes a condition. *Blood*. 2021;137(1):13-15. doi:10.1182/blood.2020008600
17. Quinn CT, Berliner N. Gene test interpretation: ACKR1 (Duffy blood group gene),. Updated September 20, 2024. <https://www.uptodate.com/contents/gene-test-interpretation-ackr1-duffy-blood-group-gene/print>
18. Uhl L. Pretransfusion testing for red blood cell transfusion Updated January 21, 2025. <https://www.uptodate.com/contents/pretransfusion-testing-for-red-blood-cell-transfusion>
19. Hu X, Zhang Z, Zeng S. *ABO-incompatible Organ Transplantation*. 2019.

20. Miller KC, Gertz MA, Buadi FK, et al. Comparable outcomes using propylene glycol-free melphalan for autologous stem cell transplantation in multiple myeloma. *Bone Marrow Transplant*. Apr 2019;54(4):587-594. doi:10.1038/s41409-018-0302-6
21. Shah GL, Landau H, Sarubbi C, et al. Pharmacokinetics and Toxicities after Evomela® (Propylene Glycol Free Melphalan) with Hematopoietic Stem Cell Transplant (HCT) for Multiple Myeloma (MM), AL Amyloidosis (AL), Lymphoma, Acute Myeloid Leukemia (AML), and Myelodysplastic Syndrome (MDS). *Biology of Blood and Marrow Transplantation*. 2018;24(3):S79–S80.
22. Yaddanapudi S, Yaddanapudi L. Indications for blood and blood product transfusion. *Indian J Anaesth*. Sep 2014;58(5):538-42. doi:10.4103/0019-5049.144648
23. Passweg JR, Baldomero H, Bader P, et al. Hematopoietic stem cell transplantation in Europe 2014: more than 40 000 transplants annually. *Bone Marrow Transplant*. Jun 2016;51(6):786-92. doi:10.1038/bmt.2016.20
24. Shokrgozar N, Tamaddon G. ABO Blood Grouping Mismatch in Hematopoietic Stem Cell Transplantation and Clinical Guides. *Int J Hematol Oncol Stem Cell Res*. Oct 1 2018;12(4):322-328.
25. Booth GS, Gehrie EA, Bolan CD, Savani BN. Clinical guide to ABO-incompatible allogeneic stem cell transplantation. *Biol Blood Marrow Transplant*. Aug 2013;19(8):1152-8. doi:10.1016/j.bbmt.2013.03.018
26. Worel N. ABO-Mismatched Allogeneic Hematopoietic Stem Cell Transplantation. *Transfus Med Hemother*. Jan 2016;43(1):3-12. doi:10.1159/000441507
27. Parkhideh S, Chegeni R, Mehdizadeh M, Roshandel E, Tavakoli F, Hajifathali A. Effects of ABO incompatibility on the outcome of allogeneic hematopoietic stem cell transplantation. *Transfus Apher Sci*. Dec 13 2019;102696. doi:10.1016/j.transci.2019.102696
28. Fasano RM, Sullivan HC, Bray RA, et al. Genotyping Applications for Transplantation and Transfusion Management: The Emory Experience. *Arch Pathol Lab Med*. Mar 2017;141(3):329-340. doi:10.5858/arpa.2016-0277-SA
29. Shankarkumar U, Ghosh K, Mohanty D. The human leucocyte antigen (HLA) system. *J Assoc Physicians India*. Jul 2002;50:916-26.
30. Ware RE, de Montalembert M, Tshilolo L, Abboud MR. Sick cell disease. *Lancet*. Jul 15 2017;390(10091):311-323. doi:10.1016/s0140-6736(17)30193-9
31. Strouse J. Sick cell disease. *Handb Clin Neurol*. 2016;138:311-24. doi:10.1016/b978-0-12-802973-2.00018-5
32. Casas J, Friedman DF, Jackson T, Vege S, Westhoff CM, Chou ST. Changing practice: red blood cell typing by molecular methods for patients with sickle cell disease. *Transfusion*. Jun 2015;55(6 Pt 2):1388-93. doi:10.1111/trf.12987
33. Brancialeoni V, Di Pierro E, Motta I, Cappellini MD. Laboratory diagnosis of thalassemia. *Int J Lab Hematol*. May 2016;38 Suppl 1:32-40. doi:10.1111/ijlh.12527
34. Dhawan HK, Kumawat V, Marwaha N, et al. Alloimmunization and autoimmunization in transfusion dependent thalassemia major patients: Study on 319 patients. *Asian J Transfus Sci*. Jul 2014;8(2):84-8. doi:10.4103/0973-6247.137438
35. Belsito A, Magnussen K, Napoli C. Emerging strategies of blood group genotyping for patients with hemoglobinopathies. *Transfus Apher Sci*. Apr 2017;56(2):206-213. doi:10.1016/j.transci.2016.11.007
36. Fasano RM, Chou ST. Red Blood Cell Antigen Genotyping for Sickle Cell Disease, Thalassemia, and Other Transfusion Complications. *Transfus Med Rev*. Oct 2016;30(4):197-201. doi:10.1016/j.tmr.2016.05.011
37. Guzijan G, Jovanovic Srzentic S, Pavlovic Jankovic N, Djilas I, Lilic M. Implementation of Molecular RHD Typing at Two Blood Transfusion Institutes from Southeastern Europe. *Transfus Med Hemother*. Apr 2019;46(2):114-120. doi:10.1159/000496751

38. Anstee DJ. Red cell genotyping and the future of pretransfusion testing. *Blood*. Jul 9 2009;114(2):248-56. doi:10.1182/blood-2008-11-146860
39. Sapatnekar S. Molecular Typing for Red Blood Cell Antigens. <https://myadlm.org/cln/articles/2015/march/molecular-typing-for-red-blood-cell-antigens>
40. Liu Z, Liu M, Mercado T, Illoh O, Davey R. Extended blood group molecular typing and next-generation sequencing. *Transfus Med Rev*. Oct 2014;28(4):177-86. doi:10.1016/j.tmr.2014.08.003
41. Wilkinson DS. Clinical Utility of Genotyping Human Erythrocyte Antigens. *Lab Med*. Aug 2016;47(3):e28-31. doi:10.1093/labmed/lmw014
42. Grifols. FDA Approves Grifols ID CORE XT Test For Molecular Red Blood Cell Typing. <https://www.prnewswire.com/news-releases/fda-approves-grifols-id-core-xt-test-for-molecular-red-blood-cell-typing-300730173.html>
43. Lopez M, Apraiz I, Rubia M, et al. Performance evaluation study of ID CORE XT, a high throughput blood group genotyping platform. *Blood Transfus*. Feb 2018;16(2):193-199. doi:10.2450/2016.0146-16
44. Immuncor. PreciseType™ HEA (human erythrocyte antigen) - NEW Test of Record for Extended Blood Cell Antigen Typing. <https://www.immucor.com/en-us/Products/Pages/PreciseType-HEA.aspx>
45. Lambda O. LinkSeq™ PCR Typing Kits. <https://www.thermofisher.com/onelambda/us/en/pre-transplant/hla-typing/linkseq.html>
46. Sippert. Accuracy of Blood Group Typing in the Management and Prevention of Alloimmunization. *Human Blood Group Systems and Haemoglobinopathies*. 2019;
47. Muro T, Fujihara J, Imamura S, et al. Determination of ABO genotypes by real-time PCR using allele-specific primers. *Leg Med (Tokyo)*. Jan 2012;14(1):47-50. doi:10.1016/j.legalmed.2011.10.002
48. Krog GR, Rieneck K, Clausen FB, Steffensen R, Dziegiel MH. Blood group genotyping of blood donors: validation of a highly accurate routine method. *Transfusion*. Oct 2019;59(10):3264-3274. doi:10.1111/trf.15474
49. Wagner FF, Flegel WA, Bittner R, Doscher A. Molecular typing for blood group antigens within 40 min by direct polymerase chain reaction from plasma or serum. *Br J Haematol*. Mar 2017;176(5):814-821. doi:10.1111/bjh.14469
50. Dezan MR, Ribeiro IH, Oliveira VB, et al. RHD and RHCE genotyping by next-generation sequencing is an effective strategy to identify molecular variants within sickle cell disease patients. *Blood Cells Mol Dis*. Jun 2017;65:8-15. doi:10.1016/j.bcmd.2017.03.014
51. Shah A, Patel P, Patel K, et al. Comparison of serology and molecular detection of common red cell antigens in multitransfused thalassemia major and sickle cell disease patients. *Transfus Apher Sci*. Jul 9 2019;102599. doi:10.1016/j.transci.2019.06.026
52. Sheppard CA, Bolen NL, Meny G, Kalvelage M, Ochoa-Garay G. Concordance of two polymerase chain reaction-based blood group genotyping platforms for patients with sickle cell disease. *Immunohematology*. Dec 2020;36(4):123-128.
53. Jadhao S, Davison CL, Roulis EV, et al. RBCeq: A robust and scalable algorithm for accurate genetic blood typing. *eBioMedicine*. 2022/02/01/ 2022;76:103759.
54. Flegel WA, Gottschall JL, Denomme GA. Integration of red cell genotyping into the blood supply chain: a population-based study. *Lancet Haematol*. Jul 2015;2(7):e282-9. doi:10.1016/s2352-3026(15)00090-3
55. Shih AW, Yan MTS, Elahie AL, et al. Utilising red cell antigen genotyping and serological phenotyping in sickle cell disease patients to risk-stratify patients for alloimmunisation risk. *Transfusion Medicine*. 2020;30(4):263-274.

56. Vege S, Sprogøe U, Lomas-Francis C, et al. Impact of RHD genotyping on transfusion practice in Denmark and the United States and identification of novel RHD alleles. *Transfusion*. 2021;61(1):256-265. doi:10.1111/trf.16100
57. MTSC. Standards for Molecular Testing for Red Cell, Platelet and Neutrophil Antigens, 2nd edition. <https://www.aabb.org/standards-accreditation/standards/molecular-testing-for-red-cell-platelet-and-neutrophil-antigens>
58. Chou ST, Alsawas M, Fasano RM, et al. American Society of Hematology 2020 guidelines for sickle cell disease: transfusion support. *Blood Adv*. Jan 28 2020;4(2):327-355. doi:10.1182/bloodadvances.2019001143
59. Milkins C, Berryman J, Cantwell C, et al. Guidelines for pre-transfusion compatibility procedures in blood transfusion laboratories. British Committee for Standards in Haematology. *Transfus Med*. Feb 2013;23(1):3-35. doi:10.1111/j.1365-3148.2012.01199.x
60. Davis BA, Allard S, Qureshi A, et al. Guidelines on red cell transfusion in sickle cell disease. Part I: principles and laboratory aspects. *Br J Haematol*. Jan 2017;176(2):179-191. doi:10.1111/bjh.14346
61. White J, Qureshi H, Massey E, et al. Guideline for blood grouping and red cell antibody testing in pregnancy. *Transfus Med*. Aug 2016;26(4):246-63. doi:10.1111/tme.12299
62. Regan F, Veale K, Robinson F, et al. Guideline for the investigation and management of red cell antibodies in pregnancy: A British Society for Haematology guideline. *Transfus Med*. Feb 2025;35(1):3-23. doi:10.1111/tme.13098
63. EDQM. Guide to the preparation, use and quality assurance of BLOOD COMPONENTS. 2023;21
64. Compernolle V, Chou ST, Tanael S, et al. Red blood cell specifications for patients with hemoglobinopathies: a systematic review and guideline. *Transfusion*. Jun 2018;58(6):1555-1566. doi:10.1111/trf.14611
65. Trompeter S, Massey E, Robinson S, Committee tTTFotBSHG. Position paper on International Collaboration for Transfusion Medicine (ICTM) Guideline 'Red blood cell specifications for patients with hemoglobinopathies: a systematic review and guideline'. *British Journal of Haematology*. 2020;189(3):424-427. doi:10.1111/bjh.16405
66. NHLBI. Evidence-Based Management of Sickle Cell Disease. https://www.nhlbi.nih.gov/sites/default/files/media/docs/sickle-cell-disease-report%20020816_0.pdf
67. Taher A, Musallam K, Cappellini MD. In: Weatherall D, ed. *Guidelines for the Management of Non Transfusion Dependent Thalassaemia (NTDT) 2nd Edition*. Thalassaemia International Federation (c) 2013 Thalassaemia International Federation.; 2018.
68. Cappellini MD, Cohen A, Porter J, Taher A, Viprakasit V. *Guidelines for the Management of Transfusion Dependent Thalassaemia (TDT)* Thalassaemia International Federation; 2014.
69. TIF. 2021 GUIDELINES FOR THE MANAGEMENT OF TRANSFUSION DEPENDENT THALASSAEMIA (TDT). <https://thalassaemia.org.cy/publications/tif-publications/guidelines-for-the-management-of-transfusion-dependent-thalassaemia-4th-edition-2021-v2/>
70. Musallam KM, Cappellini MD, Porter JB, et al. TIF Guidelines for the Management of Transfusion-Dependent β -Thalassaemia. *Hemasphere*. Mar 2025;9(3):e70095. doi:10.1002/hem3.70095
71. A. Breda KB, A. Figueiredo, E. Lledó García, J. Olsburgh (Vice-chair), H. Regele R. Boissier, V. Hevia, O. Rodríguez Faba, R.H. Zakri C. Bezuidenhout. European Association of Urology Guidelines on Renal Transplantation. *Eur Urol Focus*. 2024;
72. Mandelbrot DA, Reese PP, Garg N, et al. KDOQI US Commentary on the 2017 KDIGO Clinical Practice Guideline on the Evaluation and Care of Living Kidney Donors. *Am J Kidney Dis*. Mar 2020;75(3):299-316. doi:10.1053/j.ajkd.2019.10.005
73. Eurotransplant. Chapter 10 Histocompatibility Testing. 2024;5.4

- 74. Dehn J, Spellman S, Hurley CK, et al. Selection of unrelated donors and cord blood units for hematopoietic cell transplantation: guidelines from the NMDP/CIBMTR. *Blood*. Sep 19 2019;134(12):924-934. doi:10.1182/blood.2019001212
- 75. Cross AR. A Compendium of Transfusion Practice Guidelines. 2021;
- 76. JPAC. Chapter 13: Patient testing (red cell immunohaematology). <https://www.transfusionguidelines.org/red-book/chapter-13-patient-testing-red-cell-immunohaematology>
- 77. FDA. Immucor PreciseType Human Erythrocyte Antigen (HEA) Molecular BeadChip Test. <https://www.fda.gov/vaccines-blood-biologics/approved-blood-products/immucor-precisetype-human-erythrocyte-antigen-hea-molecular-beadchip-test>
- 78. FDA. ID CORE XT (Reagents and Analysis Software). <https://www.fda.gov/vaccines-blood-biologics/approved-blood-products/id-core-xt-reagents-and-analysis-software>

X. Review/Revision History

Effective Date	Summary
10/15/2025	Reviewed and Updated: Updated the background, guidelines and recommendations, and evidence-based scientific references. Literature review did not necessitate any modifications to coverage criteria. The following changes were made for clarity and consistency: In the Note, change “2” to “two” for consistency.
12/01/2024	Reviewed and Updated: Updated background, guidelines, and evidence-based scientific references. Literature review necessitated the following changes in coverage criteria: Addition of new CC1.h.: “h) For individuals with suspected Duffy-null neutropenia.” Note was updated to reflect changes to Avalon’s definition of a genetic panel within R2162. Now reads: “Note: For 2 or more gene tests being run on the same platform, please refer to AHS-R2162-Reimbursement Policy.” Updated code description (missing test name) for CPT code 0195U
12/01/2024	Initial Policy Implementation